ANDA 206750, held by Zydus Pharms. Temozolomide.
As of Nov 16, 2026, ANDA 206750 (Temozolomide), held by Zydus Pharms, was first approved by FDA on Jul 31, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2017 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Rx |
| Temozolomide20MG · capsule;oral | Temozolomide | Rx |
| Temozolomide100MG · capsule;oral | Temozolomide | Rx |
| Temozolomide140MG · capsule;oral | Temozolomide | Rx |
| Temozolomide180MG · capsule;oral | Temozolomide | Rx |
| Temozolomide250MG · capsule;oral | Temozolomide | Rx |
| Jul 30, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters